Exceptional revenue growth near 63% per year and three consecutive earnings beats demonstrate strong commercial momentum, but deeply negative free cash flow consuming roughly 89% of revenues, below-floor business quality, and a technical setup that has not yet confirmed a resumption of trend strength combine to limit the investable case despite the growth trajectory.
Thesis pillars
- Exceptional Revenue Growth Rate→Stable
- Improving Earnings Beat Cadence→Stable
- Severe Cash Burn Viability Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Kestra Medical Technologies, Lt (KMTS) Stock Analysis
Breakout setup
Healthcare · Medical Instruments & Supplies
Sell if holding. At $27.14, A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ASSURE WCD; Concentration risk — Supplier: primary suppliers.
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device company that develops and leases the ASSURE wearable cardioverter defibrillator (WCD) to protect patients at elevated risk of sudden cardiac arrest, the centerpiece of its Cardiac Recovery System... Read more
Sell if holding. At $27.14, A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ASSURE WCD; Concentration risk — Supplier: primary suppliers. Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Score 5.2/10, moderate confidence.
Passes 6/8 gates (positive momentum, no SEC red flags, news events none recent, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: aggressive.
About Kestra Medical Technologies, Lt
About Kestra Medical Technologies, Lt
Kestra Medical Technologies generated $59.8 million in revenue for fiscal 2025, up 115% from $27.8 million a year earlier, almost entirely from leasing its ASSURE wearable cardioverter defibrillator, which received FDA premarket approval in July 2021 and launched commercially in August 2022. The global WCD market reached $1.3 billion in 2023, about 85% generated in the U.S., where ASSURE competes against a single incumbent that held the market exclusively for over 20 years.
Kestra earns revenue by leasing the ASSURE WCD to patients on a month-to-month basis and billing third-party payors — Medicare, Medicaid, private insurers, and other healthcare organizations — directly for the device's use, supplemented by co-insurance and deductible billing to patients. As of April 30, 2025, about 285 million U.S. lives were covered under insurance contracts that include the ASSURE WCD, representing roughly 90% of total available lives. The company distributes through a U.S. commercial organization of approximately 80 direct sales representatives and more than 40 clinical support professionals, backed by a contracted network of over 300 patient specialists who handle device fitting and training; devices are reprocessed and returned to the distribution network after each patient's wear period, with each unit designed for about three patient wears per year. Kestra scaled its team from 66 employees in October 2020 to more than 330 as of April 30, 2025, alongside a patent and trade-secret portfolio exceeding 365 pending and issued filings.
Show full overview
Kestra's single-product dependency compounds into its supply chain: the 10-K lists the inability to obtain sufficient and timely component supplies, or to secure second-source suppliers if primary suppliers cannot fulfill orders, as a named risk to the business — meaningful because, as the filing itself acknowledges, nearly all of Kestra's revenue flows through this single device. Unlike diversified medical device makers that can absorb a supply disruption in one product line, a shortfall from a primary ASSURE WCD component supplier would hit the company's entire commercial revenue base at once, not just a segment of it.
See also: Healthcare · Medical Instruments & Supplies
From Kestra Medical Technologies, Lt's most recent 10-K filing, extracted August 30, 2026.
Recent developments
updated 2026-09-26Recent Developments — Kestra Medical Technologies, Lt
Latest news
- NEWS Kestra Medical Technologies Appoints Daniel Finney as Vice President of Research & Development - Quiver Quantitative — Quiver Quantitative positive
- NEWS Kestra Medical Technologies Appoints Daniel Finney as Vice President of Research & Development - quiverquant.com — quiverquant.com positive
- NEWS KESTRA MEDICAL TECHNOLOGIES Q1 2027 Earnings Preview: Recent $KMTS Insider Trading, Hedge Fund Activity, and More - Quiv — Quiver Quantitative neutral
- NEWS KESTRA MEDICAL TECHNOLOGIES Q1 2027 Earnings Preview: Recent $KMTS Insider Trading, Hedge Fund Activity, and More - quiv — quiverquant.com neutral
- NEWS Kestra Medical Technologies (KMTS) Fiscal Q1 2027 Earnings Call: Revenue Up 60%, Guidance Raised - TradingKey — TradingKey positive
Generated 2026-09-26T16:02:03Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHProductASSURE WCD10-K Item 1A: 'We generate revenue primarily from the lease of our ASSURE WCD as part of our Cardiac Recovery System platform, and we are therefore highly dependent on our ASSURE WCD for our continued success.'
- HIGHSupplierprimary suppliers10-K Item 1A: 'our inability to obtain sufficient and timely supplies of components necessary to manufacture our products or secure second source suppliers if our primary suppliers are unable to fulfill our orders'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $27.14, A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ASSURE WCD; Concentration risk — Supplier: primary suppliers. Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Prior stop was $25.24. Score 5.2/10, moderate confidence.
Take-profit target: $31.21 (-2.9% upside). Prior stop was $25.24. Stop-loss: $25.24.
Concentration risk — Product: ASSURE WCD; Concentration risk — Supplier: primary suppliers; Analyst target reached - limited upside remaining.
Kestra Medical Technologies, Lt trades at a P/E of N/A (forward -12.5). TrendMatrix value score: 2.6/10. Verdict: Sell.
14 analysts cover KMTS with a consensus score of 4.3/5. Average price target: $30.
What does Kestra Medical Technologies, Lt do?Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device company that develops and leases the...
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device company that develops and leases the ASSURE wearable cardioverter defibrillator (WCD) to protect patients at elevated risk of sudden cardiac arrest, the centerpiece of its Cardiac Recovery System platform. The company generated $59.8 million in revenue for fiscal 2025 (up 115% year-over-year), with a $113.8 million net loss and $520.2 million accumulated deficit, competing against a single incumbent that held the WCD market for over 20 years.